Alnylam reports positive topline results from helios-b phase 3 study of vutrisiran, achieving statistical significance on primary and all secondary endpoints in both overall and monotherapy populations

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced positive topline results from its helios-b phase 3 study of vutrisiran, an investigational rnai therapeutic in development for the treatment of attr amyloidosis with cardiomyopathy (attr-cm). the study met the primary endpoint, demonstrating a statistically significant reduction in the composite of all-cause mortality and recurrent cardiovascular (cv) events du.
ALNY Ratings Summary
ALNY Quant Ranking